TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
TransMedics Group, Inc. has announced the completion of its strategic investment in PAD Aviation service GmbH, a German-based private aviation operator. This investment is crucial for TransMedics to establish a dedicated pan-European organ transplantation air logistics network, aiming to expand the adoption of its OCS perfusion technology and increase the utilization of donor organs across Europe. TransMedics plans to replicate its successful U.S. National OCS Program (NOP) model in Europe, partnering with PAD Aviation to enhance organ transplant activities and save more lives.
TMDX - Transmedics Group Inc Latest SEC Filings
This article provides the latest SEC filings information for Transmedics Group Inc (TMDX), along with comprehensive financial data. It includes key figures such as market capitalization, income, sales, various financial ratios, stock performance metrics, and analyst recommendations.
3 Growth Stocks to Buy on the Dip
This article suggests three growth stocks—SoFi Technologies, Robinhood Markets, and TransMedics Group—that investors should consider buying after recent dips in their stock prices. Despite facing challenges such as short-seller reports or disappointing quarterly results, all three companies show strong long-term prospects, innovative business models, and significant growth opportunities. The author emphasizes that buying during temporary pullbacks can lead to above-average returns.
TMDX Stock Rallies As Analyst Sees 77% Upside — Here’s Why
TransMedics Group Inc (TMDX) stock rallied after TD Cowen maintained a 'Buy' rating and a $120 price target, citing strong growth in U.S. transplant activity, particularly in heart, liver, and lung procedures, as a key driver for the company's Organ Care System (OCS) technology and logistics business. The company reported a 21% year-over-year revenue increase in Q1 2026, with Cowen's analysis suggesting significant operational scaling and a 77% potential upside from its last closing price. Retail sentiment on Stocktwits remained bullish, reflecting broader market optimism for TMDX despite a 44% year-to-date decline.
TMDX Stock Rallies As Analyst Sees 77% Upside — Here’s Why
TransMedics Group Inc (TMDX) saw its stock rally after TD Cowen maintained a 'Buy' rating and a $120 price target, implying a 77% upside. This optimism is driven by growing U.S. transplant activity, particularly in heart, liver, and lung procedures, which boosts demand for TransMedics' Organ Care System (OCS) technology and logistics services. The company reported a 21% year-over-year revenue increase in Q1 2026, reaching $173.9 million, indicating continued strong financial performance.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TransMedics Group, Inc. (TMDX) is positioned for growth due to its innovative Organ Care System (OCS) technology and solid first-quarter 2026 results. Despite a year-to-date stock decline and gross margin pressures, the company's robust pipeline, including next-generation OCS systems and expansion into new organ markets like kidney transplantation, supports its long-term strategy. Analysts maintain a "Hold" rating, while the company continues to invest in expansion and clinical programs.
TransMedics Group (NASDAQ:TMDX) Earns Buy Rating from Canaccord Genuity Group
Canaccord Genuity Group has reiterated a "buy" rating for TransMedics Group (NASDAQ:TMDX) with a $124.00 price target, suggesting a potential upside of 88.28%. Despite this, the stock was down 2.1% to $65.86, trading well below its 52-week high. The company's recent earnings showed mixed results with EPS missing estimates but revenue increasing by 21.2% year-over-year.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TransMedics Group, Inc. (TMDX) is in a good position for future growth, primarily due to its advanced Organ Care System (OCS) technology and solid first-quarter 2026 results. The company's OCS technology minimizes ischemic injury and improves organ viability, positioning it as a leader in the transplant market. However, TransMedics faces ongoing pressure on its gross margin due to investments in expansion and clinical programs.
Liquidity Mapping Around (TMDX) Price Events
This article provides an AI-generated liquidity mapping and trading strategies for Transmedics Group Inc. (NASDAQ: TMDX). Key findings indicate near-term weak sentiment, with no clear price positioning signal and elevated downside risk. The analysis offers specific institutional trading strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for different horizons.
Price to sales forward of TransMedics Group, Inc. – NASDAQ:TMDX
The article provides a snapshot of the forward price-to-sales ratio for TransMedics Group, Inc. (NASDAQ: TMDX). While the specific value is not detailed in the provided text, it indicates that the information regards a financial metric for the company. The content appears to be an extract from a financial data platform.
TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by TransMedics Group, Inc. (TMDX). The firm is encouraging investors who purchased TransMedics securities prior to February 3, 2022, and still hold them, to contact them to learn more and assist with the investigation. The firm operates on a contingency fee basis to recover investor capital and ensure corporate accountability.
TransMedics Group, Inc. Actuals & Estimates (NASDAQ:TMDX)
This article provides an overview of TransMedics Group, Inc. (NASDAQ: TMDX) stock, including its current price, historical performance, analyst forecasts, and financial data. It details key metrics like market capitalization, earnings, revenue, and EBITDA, while also offering insights into the company's employee count and earnings report schedule. The piece concludes with information on stock volatility, technical analysis ratings, and general advice on investing in TMDX.
TransMedics Group, Inc. Trade Ideas — DUS:8T8
This article compiles various trade ideas and analyses for TransMedics Group, Inc. (DUS:8T8, NASDAQ:TMDX) from different contributors on TradingView. The discussions cover recent price action, earnings reports, technical indicators like EMAs and support/resistance levels, and fundamental analysis such as expansion plans and Q2 performance. Many contributors express a bullish outlook, with some suggesting specific entry points, price targets, and risk management strategies for both short-term leverage plays and long-term investments.
TransMedics Group, Inc. Actuals & Estimates (MUN:8T8)
This article provides an overview of TransMedics Group, Inc. (MUN:8T8) stock, including its current price, performance, analyst forecasts, and financial data. It highlights the company's valuation metrics, market capitalization, earnings, revenue, and employee count. The article also mentions the upcoming earnings report date and discusses whether the company pays dividends.
Enterprise value to revenue forward of TransMedics Group, Inc. – SWB:8T8
This article displays the "Enterprise value to revenue forward" for TransMedics Group, Inc. (SWB:8T8) on the Stuttgart Stock Exchange. The current market status is closed with no trades. The period value and change are presented, noting that the data is made by humans.
Price to book forward of TransMedics Group, Inc. – NASDAQ:TMDX
This article provides financial information for TransMedics Group, Inc. (NASDAQ: TMDX), specifically focusing on its price-to-book forward ratio. It is a data-focused page from TradingView, indicating various financial metrics and market data access for the company. The content appears to be a specific landing page for financial details rather than a detailed analytical article.
Price to book forward of TransMedics Group, Inc. – SWB:8T8
This article provides the "Price to book forward" value for TransMedics Group, Inc. (SWB:8T8) on the Stuttgart Stock Exchange. The current value is not traded ("No trades") and indicates that the market is closed. The data is presented within the context of basic financial information for the company.
Virtu Financial LLC Buys 22,202 Shares of TransMedics Group, Inc. $TMDX
Virtu Financial LLC significantly increased its stake in TransMedics Group, acquiring 22,202 additional shares to own a total of 26,949 shares worth $3.28 million. Other institutional investors also adjusted their positions, meaning institutions now own 99.67% of the stock. Despite this strong institutional ownership, analyst ratings are mixed with a consensus "Hold" and an average price target of $134.50, and the company recently missed EPS expectations.
Lost Money on TransMedics Group, Inc.(TMDX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Levi & Korsinsky LLP has filed a class action securities lawsuit against TransMedics Group, Inc. (NASDAQ:TMDX) to recover losses for shareholders who were allegedly affected by securities fraud between February 28, 2023, and January 10, 2025. The lawsuit claims TransMedics used improper business tactics, including kickbacks and fraudulent overbilling, and concealed safety issues. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky to learn about their rights to seek recovery.
TransMedics Group Jumps 6.6% Amid Sector-Wide Rally
TransMedics Group (TMDX) saw its shares rise by 6.6% to $78.06 during a sector-wide rally in the medical device industry. The surge was part of a broader movement that also saw other companies like NVST, CHRN, and BFLY experience significant gains, suggesting a renewed investor optimism in the sector. The rally was supported by recent positive analyst sentiment, with one firm raising its price target for TransMedics, and market observers are watching to see if this sector rotation will continue.
TransMedics Group Jumps 6.6% Amid Sector-Wide Rally
TransMedics Group saw its shares jump 6.6% on Thursday, reaching $78.06, as the medical device sector experienced a widespread rally. This surge came amidst similar gains by other medical device companies, suggesting a broader investor optimism in the sector. The stock's positive movement is further supported by recent analyst upgrades, and investors are advised to monitor whether this sector rotation will be sustained.
Stifel raises TransMedics stock price target on strong flight data
Stifel raised its price target on TransMedics Group (NASDAQ:TMDX) to $80 from $75, maintaining a Hold rating, due to strengthening flight data points that suggest a solid second-quarter 2026 revenue beat. Despite a year-to-date stock decline, the company shows strong revenue growth and appears undervalued. However, the firm has concerns about potential future competition and recent Q1 2026 earnings fell short of expectations.
TransMedics Group (NASDAQ:TMDX) Price Target Raised to $80.00
Stifel Nicolaus has raised its price target for TransMedics Group (NASDAQ:TMDX) from $75.00 to $80.00, maintaining a "hold" rating, which suggests a potential upside of 9.26%. This comes despite the company reporting mixed recent results, missing EPS estimates but achieving near-expected revenue with 21.2% year-over-year growth. Analyst sentiment for TMDX is generally mixed, with an average "Hold" rating and a consensus price target of $134.50 among thirteen analysts.
Why (TMDX) Price Action Is Critical for Tactical Trading
This article analyzes Transmedics Group Inc. (NASDAQ: TMDX) using AI models to provide trading strategies for various risk profiles. It highlights mixed sentiment, potential for lower price levels, and elevated downside risk based on technical signals. The analysis includes position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
TransMedics (TMDX) director exercises 19,285 options and sells shares
TransMedics Group director Thomas J. Gunderson exercised stock options for 19,285 shares and simultaneously sold 9,624 shares at $75.06 each. This sale was primarily to cover the exercise price of $2.21 per share and tax withholding obligations. Following these transactions, Gunderson directly holds 26,266 common shares, indicating an increase in his overall equity exposure from this specific grant.
Transmedics Group Inc (TMDX) Valuation: PE, PB & Fair Value Analysis
Transmedics Group Inc (TMDX) has a current valuation score of 7.69, placing it 138th out of 203 companies in the Healthcare Equipment & Supplies industry. The company's P/E ratio is 15.02, which is significantly lower than its recent high but considerably higher than its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Transmedics Group Inc (TMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Transmedics Group Inc (TMDX) has an earnings forecast score of 7.85, ranking 117th in its industry, with an average price target of $148.50 from 13 analysts, most of whom recommend a "Buy". The company's expected revenue for the next quarter is $184.23 million, with an anticipated EPS of $0.56, following a previous quarter's EPS of $3.08 against an expectation of $0.21.
[144] TransMedics Group, Inc. SEC Filing
This article details a Form 144 SEC filing by TransMedics Group, Inc. (TMDX) on June 15, 2026, indicating a proposed sale of securities. The filing specifies 9,624 shares of common stock to be sold with an aggregate market value of $722,403.42, acquired through a stock option exercise, through Morgan Stanley Smith Barney LLC. The article also provides a general overview of other recent news and SEC filings for TransMedics Group.
Johnson Fistel Investigates TransMedics Group, Inc. (TMDX)
Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (TMDX) on behalf of investors who suffered losses following recent financial disclosures. The investigation focuses on whether the company complied with federal securities laws after reporting declining gross and operating margins, increased operating expenses, and forecasting lower adjusted operating margins for 2026 due to investments and higher costs. The firm is encouraging affected investors to contact them.
Johnson Fistel Investigates TransMedics Group, Inc. (TMDX)
Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (TMDX) on behalf of investors who suffered losses following recent financial disclosures. The investigation focuses on whether TransMedics complied with federal securities laws after reporting margin pressure, increased operating costs, and significant investments in growth and clinical programs. These disclosures led to a sharp decline in the company's stock price, prompting the law firm to examine potential recovery options for investors.
Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning ...
Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (NASDAQ: TMDX) on behalf of investors who may have suffered losses. This investigation follows recent financial disclosures from TransMedics, which reported increased revenue but declining gross and operating margins in Q1 2026 due to investments in growth and higher supply chain costs. The firm is examining whether TransMedics complied with federal securities laws, prompted by a sharp decline in the company's stock price after these disclosures.
TransMedics Group Jumps 5.8% Amid Sector-Wide Rally
TransMedics Group (TMDX) surged 5.8% on Tuesday, closing at $75.29, amidst a broad sector-wide rally that lifted medical device stocks. The move was attributed to a coordinated sector rotation into medical device names by institutional investors, rather than company-specific news. Investors are advised to monitor whether this sector strength is sustainable or merely a short-term technical bounce.
TransMedics Group, Inc. Trade Ideas — XETR:8T8
This article compiles various trade ideas and analyses for TransMedics Group, Inc. (TMDX) from different traders. It covers topics like recent earnings, stock performance, technical analysis indicators, and future expansion plans such as achieving full U.S. continent availability and strategic aircraft acquisition. The general sentiment among the traders leans bullish, with several recommending a "buy" position.
Price to book ratio of TransMedics Group, Inc. – XETR:8T8
This article displays the price to book ratio for TransMedics Group, Inc. (XETR:8T8) on TradingView. It provides market and financial data for the company, accessible through various features and tools on the TradingView platform. The content primarily focuses on presenting the financial metric within its user interface.
TransMedics Group, Inc. Trade Ideas — XETR:8T8
This article compiles various trading ideas and analyses for TransMedics Group, Inc. (TMDX) from different traders on TradingView. The perspectives range from bullish long-term outlooks based on strong fundamentals and technical indicators, to short-term trade setups and risk assessments. Several analyses highlight TMDX's growth, financial health, and potential for significant price increases, while also cautioning about volatility and the importance of personal research.
Oppenheimer downgrades TransMedics stock rating on sentiment concerns
Oppenheimer downgraded TransMedics Group (NASDAQ:TMDX) from Outperform to Perform due to concerns over negative market sentiment despite the company's operational performance. The stock is currently trading near its 52-week low, and analysts have revised earnings downwards for the upcoming period. Oppenheimer cited competitive assessments and upcoming uncertainties as factors for the downgrade, even though InvestingPro suggests the stock is undervalued with "GREAT" financial health.
TransMedics Group, Inc. (TMDX) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow
TransMedics Group, Inc. (TMDX) presented at the 46th Annual William Blair Growth Stock Conference on June 4, 2026, at 7:13 PM ET. The company published a slide deck in conjunction with this event. The article was written by SA Transcripts, Seeking Alpha's transcripts team.
TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?
TransMedics (TMDX) shares have fallen 4.4% since its last earnings report, underperforming the S&P 500. The company missed Q1 2026 earnings and revenue estimates, with EPS down 59.5% year-over-year and revenues up 21% but short of expectations. Despite this, TransMedics reiterated its full-year 2026 revenue guidance as growth was driven by its Organ Care System and logistics services.
TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Hold" by Brokerages
TransMedics Group, Inc. (TMDX) has received an average "Hold" rating from brokerages, based on seven hold ratings and six buy ratings from 13 analysts. The average 1-year price target is $134.00, though several firms like Piper Sandler, Canaccord Genuity, Oppenheimer, Stifel Nicolaus, and Needham recently cut price targets or downgraded the stock. This comes after the company missed Q1 earnings expectations, reporting an EPS of $0.30 against an anticipated $0.62, despite a 21.2% year-over-year revenue increase to $173.93 million.
What Drove TransMedics' Stellar Q4 2025 Performance
TransMedics Group (TMDX) significantly surpassed Q4 and full-year 2025 financial expectations, driven by strong demand for its Organ Care System (OCS) and the expanding National OCS Program (NOP). The company's future growth hinges on accelerated heart and lung OCS adoption, international expansion of the NOP, and the upcoming OCS Kidney program, despite a current premium valuation. Investors are advised to monitor international NOP adoption and R&D investments, but the stock remains a compelling "Buy" for long-term investors given its market leadership and transformative technology.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TransMedics Group (TMDX) is well-positioned for growth due to its Organ Care System (OCS) technology and robust pipeline, despite experiencing gross margin pressures. The company's innovative OCS platform, which replaces cold storage with warm perfusion for donor organs, is driving adoption and expanding into new markets like kidneys. Although profitability was impacted by investments in expansion and clinical programs, management remains focused on long-term growth and international expansion.
Stifel cuts TransMedics stock price target on heart market weakness
Stifel has lowered its price target for TransMedics Group (NASDAQ:TMDX) from $85 to $75, while maintaining a Hold rating due to weaknesses in the heart market and increased competition. The firm cited recent conversations with heart transplant surgeons who indicated a shift towards donation after circulatory death and growing sentiment for XVIVO’s device over TransMedics’ OCS. Despite these near-term headwinds and a recent earnings miss, InvestingPro analysis suggests the stock may be undervalued.
TransMedics Group, Inc. (TMDX) Stock Analysis: Unveiling a 71% Potential Upside in the Medical Device Sector
TransMedics Group, Inc. (TMDX) offers a compelling investment opportunity in the medical device sector, specifically in organ transplant technology with its Organ Care System (OCS). Analysts project a potential upside of 71.01%, with target prices ranging from $85.00 to $142.00, supported by robust earnings growth expectations and strong financial health like a 45.22% return on equity and $108.8 million in free cash flow. Despite the stock trading below its moving averages and having a high RSI, its strong fundamentals and positive analyst sentiment make it attractive for long-term growth investors.
TransMedics (TMDX) director receives 2,922 RSUs in equity grant
TransMedics Group, Inc. director Thomas J. Gunderson was granted 2,922 restricted stock units (RSUs) as part of an equity award, with each RSU representing a right to receive one share of common stock at no cash cost. Following this transaction, Gunderson directly holds 6,981 shares and RSUs in total, reflecting routine compensation rather than an open-market purchase or sale. This transaction, detailed in a Form 4 SEC filing, indicates a neutral impact and sentiment on the company's stock.
Director at TransMedics (TMDX) receives 2,922 RSUs, lifting holdings to 15,056 shares
TransMedics Group, Inc. director David Weill received an equity compensation grant of 2,922 restricted stock units (RSUs), with each RSU representing a contingent right to receive one share of common stock. This grant increased his direct holdings to 15,056 shares of TransMedics common stock. The award is considered routine compensation and not an open-market purchase.
Director at TransMedics (TMDX) receives 2,922 RSU equity grant, holds 5,788 shares
TransMedics Group, Inc. director Edward M. Basile received an equity grant of 2,922 restricted stock units (RSUs) at no cash cost. This grant increased his direct holdings to 5,788 shares of the company's common stock. The transaction, reported in a Form 4 SEC filing, represents a form of equity compensation rather than a cash purchase or open-market transaction.
TransMedics (TMDX) director receives 2,922 RSU award, holds 5,788 shares
TransMedics Group, Inc. director Stephanie Lovell was granted 2,922 restricted stock units (RSUs) on May 20, 2026, as part of a compensation-related award. These RSUs were granted at $0.00 per share, and each represents a contingent right to receive one share of TransMedics common stock. Following this transaction, Lovell directly holds a total of 5,788 shares of the company's common stock.
[Form 4] TransMedics Group, Inc. Insider Trading Activity
TransMedics Group, Inc. director James R. Tobin reported an equity award of 2,922 restricted stock units (RSUs) on May 20, 2026. This transaction was not an open-market trade but an equity award, bringing his direct holdings to 6,981 shares. Additionally, he holds indirect stakes through The Tobin 2024 Family Trust (18,000 shares) and the James R. Tobin 2012 Trust (155,146 shares).
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group, Inc. announced the grant of non-qualified stock options and restricted stock units to 14 new employees on May 19, 2026, as an inducement for their employment. These grants, including a significant portion for Senior Vice President Matthew S. Forsyth, were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $66.13, and both options and restricted stock units vest over a four-year period, subject to continued employment.
TransMedics (NASDAQ: TMDX) investors approve directors, pay, stock plan and auditor
TransMedics Group, Inc. shareholders approved key proposals at their 2026 Annual Meeting, including the election of eight directors, the non-binding advisory compensation for named executive officers, and an amendment to the 2019 Stock Incentive Plan. Additionally, PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026. These decisions reflect shareholder support for the company's governance and compensation strategies.
